Background Long-term anticoagulation is recommended in antiphospholipid syndrome with
thrombosis in order to prevent recurrences. While the current mainstay relies on vitamin K …

Purpose The treatment of thrombosis in patients with antiphospholipid syndrome (APS)
usually requires long-term anticoagulation with vitamin K antagonists. The effectiveness of …

Abstract Background Direct oral anticoagulants (DOACs) are widely used for secondary
prevention of venous thromboembolism (VTE) but their clinical efficacy and safety are not …

Background The gold standard for secondary thromboprophylaxis in APS is long term
anticoagulation with vitamin K antagonists (VKAs). Because of their widespread use and …

Objective The objective of this study was to clarify the efficacy and safety of factor Xa
inhibitors for antiphospholipid syndrome patients in real world utilization. Methods This is a …

Background Direct oral anticoagulants (DOACs) demonstrate a lower risk–benefit ratio than
vitamin K antagonists (VKAs) for secondary thromboprophylaxis of thrombotic events. But …

Background The cornerstone of thrombotic antiphospholipid syndrome (APS) patients'
management is to prevent recurrent thrombosis by long-term anticoagulation. Purpose of …

Background/Purpose Long-term anticoagulation is the standard treatment for thrombotic
antiphospholipid syndrome (APS). However, in daily practice, the question of withdrawing …

Aim The aim of this study was to describe a case series of patients with primary or secondary
antiphospholipid syndrome (APS) treated with direct oral anticoagulants (DOACs). Patients …

The direct oral anticoagulants (DOACs) are therapeutic alternatives to warfarin and other
vitamin K antagonists (VKAs), and constitute the standard of care for many indications. VKAs …